Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.

@article{OGrady1999FosinoprilhydrochlorothiazideSD,
  title={Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.},
  author={P. O'Grady and K. Yee and R. Lins and B. Mangold},
  journal={British journal of clinical pharmacology},
  year={1999},
  volume={48 3},
  pages={
          375-81
        }
}
  • P. O'Grady, K. Yee, +1 author B. Mangold
  • Published 1999
  • Medicine
  • British journal of clinical pharmacology
    • AIMS Fosinoprilat, the active product of fosinopril, is eliminated by an hepatic pathway in addition to the renal pathway shared by other angiotensin converting enzyme inhibitors (ACEIs). This study aimed to determine whether impaired renal function affects the pharmacokinetics and pharmacodynamics of a combination of fosinopril and hydrochlorothiazide (HCTZ). METHODS The study had a parallel-group design comparing patients with renal impairment and body-mass-index-matched normal controls… CONTINUE READING
    View on PubMed
    bpspubs.onlinelibrary.wiley.com
    10 Citations
    Background Citations
    2
    Methods Citations
    1
    10 Citations
    Citation Type

    Citation Type

    Population‐based meta‐analysis of hydrochlorothiazide pharmacokinetics
    • 13
    Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease
    • 11
    Development of liquid chromatographic method for fosinoprilat determination in human plasma using microemulsion as eluent.
    • 26
    Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis.
    • 44
    • PDF
    Sequential liquid-liquid extraction coupled to LC-MS/MS for simultaneous determination of amlodipine, olmesartan and hydrochlorothiazide in plasma samples: Application to pharmacokinetic studies
    • 2
    Degradation of the diuretic hydrochlorothiazide by UV/Solar radiation assisted oxidation processes.
    • 2
    • PDF
    Photocatalytic degradation of 4-amino-6-chlorobenzene-1,3-disulfonamide stable hydrolysis product of hydrochlorothiazide: Detection of intermediates and their toxicity.
    • 15
    Degradation of hydrochlorothiazide in water
    • 35
    МЕСТО ФОЗИНОПРИЛА В ЛЕЧЕНИИ ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ С ПОЗИЦИЙ ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ
    A Study on the Validity of Dosage Adjustment Using Giusti and Hayton Equation for Renally Eliminated Drugs in Patients with Renal Dysfunction: A Systematic Literature Review

    References

    SHOWING 1-8 OF 8 REFERENCES
    Pharmacokinetics of fosinopril in patients with various degrees of renal function
    • 84
    Comparison of the Steady-State Pharmacokinetics of Fosinopril, Lisinopril and Enalapril in Patients with Chronic Renal Insufficiency
    • 76
    Disposition of fosinopril sodium in healthy subjects.
    • 85
    Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function.
    • 8
    Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods.
    • 26
    Simple radioassay for measuring serum activity of angiotensin-converting enzyme in sarcoidosis.
    • 26
    Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure.
    • 37
    A Radioimmunoassay for SQ 27,519, the Active Phosphinic Acid‐Carboxylic Diacid of the Prodrug Fosinopril in Human Serum
    • 13